Tag Archives: AGIO

The CSO of Agios Pharma is Exercising Options

Today it was reported that the CSO of Agios Pharma (AGIO – Research Report), Scott Biller, exercised options to buy 7,218 AGIO shares at $2.33 a share, for a total transaction value of $16.82K. Following this transaction Scott Biller’s holding

Thursday’s Highlights at Noon: NovaBay Pharma (NBY), Kandi Technologies (KNDI), AVEO Pharma (AVEO), Agios Pharma (AGIO), OncoSec Medical (ONCS)

So far Thursday, May 16, NASDAQ is up 4.23% and the S&P is up 2.81%. Here are this morning’s most active stocks: NovaBay Pharma (NBY – Research Report), Kandi Technologies (KNDI – Research Report), AVEO Pharma (AVEO – Research Report),

Thursday’s Midday Movers: American Green Inc (ERBB), NovaBay Pharma (NBY), AVEO Pharma (AVEO), Kandi Technologies (KNDI), Agios Pharma (AGIO)

So far Thursday, May 16, NASDAQ is up 4.23% and the S&P is up 2.85%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBB – Research Report), NovaBay Pharma (NBY

Cowen & Co. Thinks Agios Pharma’s Stock is Going to Recover

Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Agios Pharma (AGIO – Research Report) yesterday. The company’s shares closed yesterday at $47.35, close to its 52-week low of $41.63. According to TipRanks.com, Shibutani is a 3-star analyst

Oppenheimer Reaffirms Their Hold Rating on Agios Pharma (AGIO)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO – Research Report). The company’s shares closed yesterday at $65.93. Breidenbach observed: “Tuesday, Agios received FDA Breakthrough Therapy Designation (BTD) for TIBSOVO in

Agios Pharma (AGIO) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $64.91. According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.1% and